
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines Ltd is positioned for significant growth, supported by a strong preference for its lead product, Brukinsa, over competing BTK inhibitors, with projected peak sales reaching approximately $7.1 billion. The company’s innovative therapeutic portfolio, including the advanced sonrotoclax, is expected to demonstrate superior efficacy and safety, potentially outperforming existing treatments like venetoclax and contributing an estimated $3.4 billion in peak sales. With strategic physician outreach and favorable market perceptions, BeOne Medicines aims for over 40% year-over-year growth in 2025, ultimately targeting profitable operations and positive free cash flow by 2025.
Bears say
BeOne Medicines Ltd faces a challenging outlook due to several key financial risks. The potential for slower-than-expected uptake of commercial products, combined with setbacks in pipeline development and regulatory hurdles, raises significant concerns about the company's ability to maintain a competitive position and achieve projected revenues. Additionally, high cash burn rates, geopolitical perceptions affecting market sentiment, and the crowded landscape of hematologic oncology could further destabilize the company's financial performance and prospects for growth.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares